UNSPSC 51333510: Domperidone maleate

This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 899U5WF46A. European Medicines Agency schedules Domperidone maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01815MIG. Domperidone maleate generally arises in the molecular formula C22H24CLN5O2.C4H4O4. The term 'domperidone maleate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule domperidone maleate under HS 29333999 and SITC 51574.

As of Q4 2014, DOMPERIDONE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)[NH]C(=O)N2CCCN3CCC(CC3)N4C5CCC(CC5[NH]C4=O)CL.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51333510 Domperidone maleate is a Commodity code that nominally names a single pharmaceutical product, but recent state and local procurement activity tagged under this code shows little direct alignment with domperidone itself. Instead, the opportunities indexed here reflect broader pharmaceutical procurement — naloxone distribution, therapeutic pharmacy initiatives, and multi-source generic pharmaceuticals and over-the-counter products. State and local issuing bodies procuring under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work solicited ranges from direct product purchase through standing contracts with authorized wholesalers to exploratory requests for information on direct-to-manufacturer prescription models.

Geographic activity spans Florida, Texas, Minnesota, and Oregon, with recent opportunities concentrated in the multistate cooperative purchasing space. Representative recent solicitations include Seminole County's IFB60459723LAS (June 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida; the Texas HHS Commission's RFI HHS0017013 (April 2026) exploring direct-to-manufacturer prescription capabilities; and MMCAP's S1070000015802 (January 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities. The MMCAP RFP is the most structured, requiring vendors to supply through authorized wholesalers with specific NDC codes, cGMP and DSCSA compliance certification, and pricing weighted 75 percent of evaluation. The mismatch between the code name and recent solicitation scope suggests this code may be misapplied in state and local systems or that domperidone procurement itself is not currently active in these jurisdictions.